(P-1655) Anti-Spike IgG4 and Fc Effector Responses: The Impact of SARS-CoV-2 Vaccine Platform–Specific Priming and Immune Imprinting

Wednesday, October 22, 2025

12:15 PM - 1:30 PM US ET

Location: Poster Hall B4-B5

Presenting Author(s)

MZ

Mingzhu Zhu, n/a

Principle Scientist
Novavax
Gaithersburg, Maryland, United States
SC

Shane Cloney-Clark, n/a

Associate Director
Novavax
Gaithersburg, Maryland, United States
AP

Anand Parekh, M.Sc.

Novavax, Inc.
Gaithersburg, Maryland, United States
DG

Drew Gorinson, B.S.

Novavax, Inc.
Gaithersburg, Maryland, United States
ZC

Zhaohui Cai, PhD

Novavax, Inc.
Gaithersburg, Maryland, United States
WM

William Moffitt, B.S.

Novavax, Inc.
Gaithersburg, Maryland, United States
MC

Miranda R. Cai, PhD

Novavax, Inc.
Gaithersburg, Maryland, United States
GC

Gordon Chau, M.S.

Novavax, Inc.
Gaithersburg, Maryland, United States
Tara M. Babu, MD, MSCI (she/her/hers)

Acting Assistant Professor
University of Washington
Seattle, Washington, United States
AW

Anna Wald, MD, MPH

Professor
University of Washington
Seattle, WA, United States
LF

Louis F. Fries, III, MD

Senior Vice President and Chief Medical Officer
Novavax, Inc.
Gaithersburg, MD, United States
LD

Lisa M. Dunkle, MD

Vice President, Global Medical Lead
Novavax, Inc.
Gaithersburg, Maryland, United States
AC

Amy W. Chung, PhD

University of Melbourne, at the Peter Doherty Institute for Infection and Immunity
Melbourne, Victoria, Australia
JP

Joyce S. Plested, n/a

Senior Director, Clinical Immunology
Novavax
Gaithersburg, Maryland, United States